TABLE 1—ESTIMATED REPORTING BURDEN [1]

Survey type	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
In-depth Interviews, Cognitive Interviews Screener	45	1	45	0.083 (5 minutes)	4
In-depth Interviews, Cognitive Interviews	9	1	9	1	9
In-depth Interviews Screener	300	1	300	0.083 (5 minutes)	25
In-depth Interviews	60	1	60	1	60
Survey Cognitive Interviews Screener	45	1	45	0.083 (5 minutes)	4
Survey Cognitive Interviews	9	1	9	1	9
Pretest survey screener	1,500	1	1,500	0.083 (5 minutes)	124
Pretest survey	300	1	300	0.25 (15 minutes)	76
Self-Administered Surveys—Study Screener	7,500	1	7,500	0.083 (5 minutes)	622.5
Self-Administered Surveys	1,500	1	1,500	0.25 (15 minutes)	375
Focus Group/Small Group, Cognitive Groups Screener	180	1	180	0.083 (5 minutes)	15
Focus Group/Small Group, Cognitive Groups	60	1	60	1.5 (90 minutes)	90
Focus Group/Small Group Participant Screening	720	1	720	0.083 (5 minutes)	60
Focus Group/Small Group Discussion	240	1	240	1.5 (90 minutes)	360
Total					1,833.5

[1] There are no capital costs or operating and maintenance costs associated with this collection of information.

Since our initial request for continued approval, we have reevaluated actual usage of individual clearance requests. Accordingly, we have adjusted our estimate downward.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–03095 Filed 2–17–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2025–N–1560]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Products Requirements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the collection of information by March 20, 2026.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under Review—Open for Public Comments'' or by using the search function. The OMB control number for this information collection is 0910–0025.

FOR FURTHER INFORMATION CONTACT: Amber Barrett, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–8867, *PRAStaff@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Electronic Products Requirements

OMB Control Number 0910–0025—Revision

Under sections 532 through 542 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360ii through 360ss), FDA has the responsibility to protect the public from unnecessary exposure of radiation from electronic products. The regulations issued under these authorities are listed in Title 21 of the Code of Federal Regulations, chapter I, subchapter J, parts 1000 through 1050 (21 CFR parts 1000 through 1050).

Section 532 of the FD&C Act directs the Secretary of Health and Human Services (the Secretary), to establish and carry out an electronic product radiation control program, including the development, issuance, and administration of performance standards to control the emission of electronic product radiation from electronic products. The program is designed to protect the public health and safety from electronic radiation, and the FD&C Act authorizes the Secretary to procure (by negotiation or otherwise) electronic products for research and testing purposes and to sell or otherwise dispose of such products. Section 534(g) of the FD&C Act directs the Secretary to review and evaluate industry testing programs on a continuing basis; and section 535(e) and (f) of the FD&C Act directs the Secretary to immediately notify manufacturers of, and ensure correction of, radiation defects or noncompliance with performance standards. Section 537(b) of the FD&C Act contains the authority to require manufacturers of electronic products to establish and maintain records (including testing records), make reports, and provide information to determine whether the manufacturer has acted in compliance.

The regulations under parts 1002 through 1010 specify reports to be provided by manufacturers and distributors to FDA and records to be maintained in the event of an investigation of a safety concern or a product recall. FDA conducts laboratory compliance testing of products covered by regulations for product standards in parts 1020, 1030, 1040, and 1050.

FDA details product-specific performance standards that specify information to be supplied with the product or require specific reports. The information collections are either specifically called for in the FD&C Act or were developed to aid the Agency in performing its obligations under the FD&C Act. The data reported to FDA and the records maintained are used by FDA and the industry to make decisions and take actions that protect the public from radiation hazards presented by electronic products. This information refers to the identification of, location of, operational characteristics of, quality assurance programs for, and problem identification and correction of electronic products. The data provided to users and others are intended to encourage actions to reduce or eliminate radiation exposures.

FDA uses the following forms to aid respondents in the submission of information for this information collection:

- Form FDA 2579 ''Report of Assembly of a Diagnostic X-Ray System''
- Form FDA 2767 ''Notice of Availability of Sample Electronic Product''
- Form FDA 2877 ''Declaration for Imported Electronic Products Subject to Radiation Control Standards''
- Form FDA 3626 ''A Guide for the Submission of Initial Reports on Diagnostic X-Ray Systems and Their Major Components''
- Form FDA 3627 ''Diagnostic X-Ray CT Products Radiation Safety Report''
- Form FDA 3628 ''General Annual Report (Includes Medical, Analytical, and Industrial X-Ray Products Annual Report)''
- Form FDA 3629 ''Abbreviated Report''
- Form FDA 3630 ''Guide for Preparing Product Reports on Sunlamps and Sunlamp Products''
- Form FDA 3631 ''Guide for Preparing Annual Reports on Radiation Safety Testing of Sunlamp Products''
- Form FDA 3632 ''Guide for Preparing Product Reports on Lasers and Products Containing Lasers''
- Form FDA 3633 ''General Variance Request''
- Form FDA 3634 ''Television Products Annual Report''
- Form FDA 3635 ''Laser Light Show Notification''
- Form FDA 3636 ''Guide for Preparing Annual Reports on Radiation Safety Testing of Laser and Laser Light Show Products''
- Form FDA 3637 ''Laser Original Equipment Manufacturer (OEM) Report''
- Form FDA 3638 ''Guide for Filing Annual Reports for X-Ray Components and Systems''
- Form FDA 3639 ''Guidance for the Submission of Cabinet X-Ray System Reports Pursuant to21 CFR 1020.40''
- Form FDA 3640 ''Reporting Guide for Laser Light Shows and Displays''
- Form FDA 3147 ''Application for a Variance From21 CFR 1040.11(c) for a Laser Light Show, Display, or Device''
- Form FDA 3641 ''Cabinet X-Ray Annual Report''
- Form FDA 3642 ''General Correspondence''
- Form FDA 3643 ''Microwave Oven Products Annual Report''
- Form FDA 3644 ''Guide for Preparing Product Reports for Ultrasonic Therapy Products''
- Form FDA 3645 ''Guide for Preparing Annual Reports for Ultrasonic Therapy Products''
- Form FDA 3646 ''Mercury Vapor Lamp Products Radiation Safety Report''
- Form FDA 3647 ''Guide for Preparing Annual Reports on Radiation Safety Testing of Mercury Vapor Lamps''
- Form FDA 3649 ''Accidental Radiation Occurrence (ARO)''
- Form FDA 3649C ''Consumer Accidental Radiation Occurrence Report''
- Form FDA 3659 ''Reporting and Compliance Guide for Television Products''
- Form FDA 3660 ''Guidance for Preparing Reports on Radiation Safety of Microwave Ovens''
- Form FDA 3661 ''A Guide for the Submission of an Abbreviated Report on X-Ray Tables, Cradles, Film Changers, or Cassette Holders Intended for Diagnostic Use''
- Form FDA 3662 ''A Guide for the Submission of an Abbreviated Radiation Safety Report on Cephalometric Devices Intended for Diagnostic Use''
- Form FDA 3663 ''Abbreviated Reports on Radiation Safety for Microwave Products (Other than Microwave Ovens)''
- Form FDA 3801 ''Guide for Preparing Initial Reports and Model Change Reports on Medical Ultraviolet Lamps and Products Containing Such Lamps''

The respondents to this information collection are electronic product and x-ray manufacturers, importers, consumers, and assemblers. The burden estimates were derived by consultation with FDA and industry personnel, and are based on data collected from industry, including product report submissions. An evaluation of the type and scope of information requested was also used to derive some time estimates.

In the **Federal Register** of July, 14, 2025 (90 FR 31211), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN [1]

Activity/21 CFR section	FDA form	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Product reports—1002.10(a)–(k)	3639—Cabinet x-ray, 3632—Laser, 3640—Laser light show, 3630—Sunlamp, 3659—TV, 3660—Microwave oven, 3801—UV lamps.	1,686	2.2	3,709	24	89,016
Supplemental reports—1002.11(a)–(b).		484	2.5	1,210	0.5 (30 minutes)	605
Abbreviated reports—1002.12	3629—General abbreviated report, 3646—Mercury vapor lamp products radiation safety report, 3663—Microwave products (non-oven).	80	1.8	144	5	720
Annual reports—1002.13(a)–(b)	3628—General, 3634—TV, 3641—Cabinet x-ray, 3643—Microwave oven, 3636—Laser, 3631—Sunlamp.	2,344	1.3	3,047	18	54,846
Accidental radiation occurrence reports—1002.20.	3649—ARO	96	4	384	2	768
Accidental radiation occurrence reports—1002.20.	3649S—ARO Summary	4	4	16	10	160
Accidental radiation occurrence reports—1002.20.	3649C—Consumer ARO	10	1	10	0.25	3
Exemption requests—1002.50(a) and 1002.51.	3642—General correspondence	5	1.3	7	1	7
Product and sample information—1005.10.	2767—Sample product	10	1	10	0.1 (6 minutes)	1
Identification information and compliance status—1005.25.	2877—Imports declaration	14,506	67	971,902	0.2 (12 minutes)	194,380

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN [1]—Continued

Activity/21 CFR section	FDA form	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Alternate means of certification—1010.2(d).		1	1	1	5	5
Variance—1010.4(b)	3633—General variance request, 3147—Laser show variance request, 3635—Laser show notification.	580	1.1	638	1.2	766
Exemption from performance standards—1010.5(c) and (d).		1	1	1	22	22
Alternate test procedures—1010.13		1	1	1	10	10
Microwave oven exemption from warning labels—1030.10(c)(6)(iv).		1	1	1	1	1
Laser products registration—1040.10(a)(3)(i).	3637—Original equipment manufacturer (OEM) report.	42	2.9	122	3	366
Total		19,851		981,203		341,676

[1] Numbers have been rounded.

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN [1]

Activity/21 CFR section	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per recordkeeping	Total hours
Manufacturer test and distribution records—1002.30 and 1002.31(a)	2,129	1,650	3,512,850	0.12 (7 minutes)	421,542
Dealer/distributor records—1002.40 and 1002.41	3,000	50	150,000	0.05 (3 minutes)	7,500
Information on diagnostic x-ray systems—1020.30(g)	50	1	50	0.5 (30 minutes)	25
Laser products distribution records—1040.10(a)(3)(ii)	121	1	121	1	121
Total	5,300		3,663,021		429,188

[1] Numbers have been rounded.

TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN

Activity/21 CFR section	FDA form	Number of respondents	Number of disclosures per respondent	Total annual disclosures	Average burden per disclosure	Total hours [1]
Technical and safety information for users—1002.3		1	1	1	12	12
Dealer/distributor records—1002.40 and 1002.41		30	3	90	1	90
Television receiver critical component warning—1020.10(c)(4).		1	1	1	1	1
Cold cathode tubes—1020.20(c)(4)		1	1	1	1	1
Report of assembly of diagnostic x-ray components—1020.30(d), (d)(1), and (d)(2).	FDA 2579—Assembler report.	1,235	34	41,990	0.30 (18 minutes)	12,597
Information on diagnostic x-ray systems—1020.30(g)		6	1	6	55	330
Statement of maximum line current of x-ray systems—1020.30(g)(2).		6	1	6	10	60
Diagnostic x-ray system safety and technical information—1020.30(h)(1)–(h)(4).		6	1	6	200	1,200
Fluoroscopic x-ray system safety and technical information—1020.30(h)(5)–(h)(6) and 1020.32(a)(1), (g), and (j)(4).		5	1	5	25	125
CT equipment—1020.33(c)–(d), (g)(4), and (j)		5	1	5	150	750
Cabinet x-ray systems information—1020.40(c)(9)(i)–(c)(9)(ii).		6	1	6	40	240
Microwave oven radiation safety instructions—1030.10(c)(4).		1	1	1	20	20
Microwave oven safety information and instructions—1030.10(c)(5)(i)–(c)(5)(iv).		1	1	1	20	20
Microwave oven warning labels—1030.10(c)(6)(iii)		1	1	1	1	1
Laser products information—1040.10(h)(1)(i)–(h)(1)(vi)		2	1	2	20	40
Laser product service information—1040.10(h)(2)(i)–(h)(2)(ii).		2	1	2	20	40
Medical laser product instructions—1040.11(a)(2)		2	1	2	10	20
Sunlamp products instructions—1040.20		1	1	1	10	10
Mercury vapor lamp labeling—1040.30(c)(1)(ii)		1	1	1	1	1
Mercury vapor lamp permanently affixed labels—1040.30(c)(2).		1	1	1	1	1
Total		1,314		42,129		15,559

[1] Total hours have been rounded.

Our estimated burden for the information collection reflects an overall increase of 381,821 hours and a corresponding increase of 2,135,962 responses/records.

We attribute this adjustment to the addition of the new FDA Form 3649C to this collection and the adjustment to an

increase in respondents in the number of submissions we received over the last few years.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–03097 Filed 2–17–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Topics on neurodevelopment, neurodegeneration, and the blood brain barrier.

Date: March 17, 2026.

Time: 9:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Eric S. Tucker, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 451–1141, *eric.tucker@nih.gov.*

Name of Committee: Oncology 1-Basic Translational Integrated Review Group; Tumor Evolution, Heterogeneity and Metastasis Study Section.

Date: March 18–19, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 443–9734, *Stoicaa2@mail.nih.gov.*

Name of Committee: Applied Therapeutics for Cancer Integrated Review Group; Drug Discovery and Molecular Pharmacology C Study Section.

Date: March 20, 2026.

Time: 8:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Alireza S. Alavi, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–4108, *ali.alavi@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Complementary and Integrative Health Approaches and Mind and Body Interventions.

Date: March 20, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Sonia Elena Nanescu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–8163, *sonia.nanescu@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–CA–25–002: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33).

Date: March 20, 2026.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20852.

Meeting Format: Virtual Meeting.

Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 6188, MSC 7804, Bethesda, MD 20892, 301–435–1267, *belangerm@csr.nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Kidney, Urology, and Related Disciplines.

Date: March 20, 2026.

Time: 1:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Ryan G. Morris, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 451–1322, *ryan.morris@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 13, 2026.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–03200 Filed 2–17–26; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Biochemistry, Chemistry & Biophysics.

Date: March 3, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Dennis Pantazatos, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–2381, *dennis.pantazatos@nih.gov.*

This notice is being published less than 15 days from the meeting date due to exceptional circumstances. As a result of the government shutdown, due to lapsed appropriations, the above meeting was canceled. This meeting was to assess the scientific and technical merit of NIH grant applications, required by statute to disburse NIH funds. The meeting must take place urgently so that evaluations of biomedical research applications addressing multiple major public health priorities can be submitted to the national advisory councils for timely funding recommendations.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)